Trials and Noteworthy Treatments

			Treatment Next 25		Location		Last Updated
	Details		Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma		Charlottesville, VA		09/30/2008
	Details		A Phase I Study of Imatinib Mesylate (Gleevec) in Combination With Temozolomide (Temodar) in Patients With Malignant Glioma		Durham, NC		08/20/2007
	Details		Determination of the In-Tumor-Concentration of Imatinib Mesylate (Gleevec) in Malignant Glioma After Oral Administration		Baltimore, MD		08/20/2007
	Details		Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patients with Plexiform Neurofibromas		Dallas, TX		11/21/2006
	Details		Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma		Jacksonville, FL Jacksonville, FL Des Moines, IA Moline, IL Peoria, IL Urbana, IL Wichita, KS Lambertville, MI Rochester, MN Saint Louis Park, MN Billings, MT Bismarck, ND Lincoln, NE Danville, PA Spartanburg, SC Sioux Falls, SD		06/26/2006
	Details		Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma		Jacksonville, FL Ames, IA Cedar Rapids, IA Missouri Valley, IA Sioux City, IA Moline, IL Peoria, IL Urbana, IL Wichita, KS Lambertville, MI Duluth, MN Saint Louis Park, MN Billings, MT Bismarck, ND Lincoln, NE Allentown, PA Danville, PA Sayre, PA Spartanburg, SC Rapid City, SD Sioux Falls, SD		11/27/2005
	Details		Phase I, open-label, 2-arm dose escalation study of Imatinib Mesylate (Gleevec) in combination with Temozolomide (Temodar)in patients with glioblastoma multiforme and gliosarcoma.		Durham, NC		11/13/2005
	Details		Phase II trial of Gleevec plus hydroxyurea in the treatment of patients with malignant glioma		Durham, NC		11/13/2005

News Stories

(Relevance) Question - click to see the response!
Displaying 1 to 26 of 36
Click HERE for Next 25 articles!

(Relevance) Page Title - click title to go to the page!

•   (0.9878)   New Data Suggest Novartis Drug Gleevec(TM) (Formerly STI571) Effective In Rare Form of Gastrointestinal Tumor (PR Newswire)
  Novartis Oncology today announced that data on the activity of Gleevec(TM) in a rare form of gastrointestinal stromal tumor will be highlighted during the key plenary session of the 37th annual meeting of the American Society for Clinical Oncology in San Francisco, California.
  - May 13 12:00 PM ET
  
  
•   (0.9850)   FDA Approves Novartis` Unique Leukemia Medication Gleevec(TM)* (imatinib mesylate) (PR Newswire)
  Novartis today announced that the United States Food and Drug Administration approved its drug Gleevec(TM) as an oral therapy for the treatment of patients with chronic myeloid leukemia in the blast crisis, accelerated phase or in chronic phase after failure of interferon-alpha therapy.
  - May 10 3:34 PM ET
  
  
•   (0.9833)   Gleevec Holds Up in Long-Term Study (HealthSCOUT)
  ... the FDA also approved Gleevec for treating gastrointestinal stromal tumors (GIST), a rare form of solid cancer that affect about 5,000 Americans a year.......These range from tumors in the brain and bone to those in the skin and eyes....
  - Feb 27 11:54 PM ET
  
  
•   (0.9573)   The Leukemia & Lymphoma Society(SM) Enters Into Education Partnership With Novartis (PR Newswire)
  The Leukemia & Lymphoma Society is pleased to join in a collaborative partnership with Novartis to educate the public about Gleevec(TM), Novartis` new oral medication approved by the U.S.
  - May 10 1:52 PM ET
  
  
•   (0.9527)   Drug-Resistant Cancer Outwitted by Chemical Flank Attack
  
  
•   (0.9527)   Government Approves Novartis Cancer Drug Gleevec (Reuters)
  ... - U.S. officials on Thursday announced approval in record time for a breakthrough oral cancer drug that has shown dramatic results against a rare but deadly type of leukemia.U.S. Health and Human Services Secretary Tommy Thompson announced government approval for Novartis AG`s oral drug Gleevec for fighting chronic myeloid leukemia, a disease that causes a deadly overproduction of white blood cells....
  - May 10 4:07 PM ET
  
  
•   (0.9527)   U.S. Approves Novartis Cancer Drug Gleevec (Reuters)
  ... - U.S. officials on Thursday announced approval in record time for a breakthrough oral cancer drug that has shown dramatic results against a rare but deadly type of leukemia.U.S. Health and Human Services Secretary Tommy Thompson announced government approval for Novartis AG`s oral drug Gleevec for fighting chronic myeloid leukemia, a disease that causes a deadly overproduction of white blood cells....
  - May 10 4:09 PM ET
  
  
•   (0.9352)   Breakthrough Cancer Drug Lifts Novartis Shares (Reuters)
  ...Attention now turns to initial trial results due on Monday that may give clues about how well the innovative leukemia drug can handle solid cancerous tumors as well.......Novartis says it also inhibits two other proteins: the c-kit receptor linked to GIST and small cell lung cancers, and the PDG-F receptor, active in some kinds of brain, prostate and soft tissue cancer....
  - May 11 7:21 AM ET
  
  
•   (0.9352)   FDA Approves Novartis Cancer Drug Gleevec (Reuters)
  U.S. Health and Human Services Secretary Tommy Thompson announced on Thursday government approval for Novartis AG`s (NOVZn.S) (NVS.N) oral cancer treatment Gleevec for fighting a rare life-threatening type of leukemia.
  - May 10 2:10 PM ET
  
  
•   (0.9282)   U.S. approves Novartis cancer drug Gleevec (Reuters Securities)
  ...U.S. Health and Human Services Secretary Tommy Thompson announced government approval for Novartis AG`s oral drug Gleevec for fighting chronic myeloid leukemia, a disease that causes a deadly overproduction of white blood cells....
  - May 10 3:59 PM ET
  
  
•   (0.9115)   Combination of Gleevec® and Hydrea® Offers Promise for Glioblastoma Multiforme
  
  
•   (0.8912)   U.S. FDA approves Novartis cancer drug Gleevec (Reuters Securities)
  U.S. health officials said on Thursday they approved Novartis AG`s oral cancer treatment Gleevec for fighting a rare life-threatening type of leukemia.
  - May 10 1:32 PM ET
  
  
•   (0.8792)   Dr. Bruce A. Chabner, Editor-In-Chief of "The Oncologist" Journal, States: "STI571 (Gleevec) Represents a Monumental Leap Forward In Cancer Chemotherapy ... the Oncologic Equivalent of Breaking the Four-Minute Mile." (PR Newswire)
  ... myelogenous leukemia and in gastrointestinal stromal tumors (GIST)....... underway in prostate cancer, lung cancer, gliomas (brain tumors),...
  - Jun 25 1:50 PM ET
  
  
•   (0.8658)   Leukemia & Lymphoma Society(SM) to Provide Information on Gleevec(TM) (PR Newswire)
  ...WHAT: With expedited regulatory review of Gleevec(TM) (STI-571), the oral investigational agent from Novartis Oncology,...
  - May 08 6:06 PM ET
  
  
•   (0.8658)   ADVISORY/FDA Approves Novartis` Unique Leukemia Medication Gleevec (Business Wire)
  ...Novartis today announced that the United States Food and Drug Administration (FDA) approved its drug Gleevec(tm) (imatinib mesylate) as an oral therapy for the treatment of patients with chronic myeloid leukemia (CML) in the blast crisis,...
  - May 10 3:31 PM ET
  
  
•   (0.8658)   FDA Approves Novartis Cancer Drug (Forbes.com)
  Regulators pass Gleevec, a promising leukemia drug, after three months of review. A Forbes.com Special Report.
  - May 10 4:44 PM ET
  
  
•   (0.8510)   Targeted drug combos could outsmart cancer
  
  
•   (0.8510)   Iressa news backgrounder: Testing of smart drug expands at M. D. Anderson Cancer Center
  
  
•   (0.8351)   Medicare to Extend Access to Certain Drugs for Beneficiaries with Serious and Chronic Illnesses [Editor`s Note: includes Temodar!]
  
  
•   (0.8169)   A new approach to treating cancer
  
  
•   (0.8169)   Imatinib (STI 571) is active in patients (PTS) with high-grade gliomas progressing on standard therapy.
  
  
•   (0.7967)   Immunohistochemical Analysis of Platelet-derived Growth Factor Receptor-alpha, -beta, c-kit, c-abl, and arg Proteins in Glioblastoma: Possible Implications for Patient Selection for Imatinib Mesylate (Gleevec) Therapy.
  
  
•   (0.7967)   Oral Desensitization Prevents Recurrent Imatinib (Gleevec) Rash
  
  
•   (0.7967)   `01 Had Breakthrough in Angioplasty (AP)
  ... a new drug effective against an unusual digestive cancer called gastrointestinal stromal tumors.......It is also being tested in lung, prostate and brain cancer. Standard chemotherapy goes after all fast-dividing cells and kills them indiscriminately....
  - Dec 17 2:21 PM ET
  
  
•   (0.7742)   Novartis’s Afinitor Pill May Be ‘Mega-Blockbuster’
  
  

Frequently Asked Questions

(Relevance) Question - click to see the response!
Displaying 1 to 2 of 2